Sensorion Declares Completion of Enrollment of First Cohort of Audiogene Section 1/2 Gene Remedy Medical Trial by Investing.com
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory information: Sensorion (FR0012596468 “ALSEN) a pioneering clinical-stage biotechnology firm…
Merck-AstraZeneca’s breast most cancers drug Lynparza improves long-term survival, scientific trial finds
Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune…
Roche’s part IIb research of prasinezumab failed to fulfill main endpoint, however suggests doable medical profit in treating early-stage Parkinson’s illness
The PADOVA research confirmed a numerical delay in motor development and constructive…
Different title developer EpiPen is undervalued regardless of robust medical information, analyst sees enormous upside potential
Different title developer EpiPen is undervalued regardless of robust medical information, analyst…
SINOVAC Initiated Section III Medical Trial of Bivalent Hand, Foot, and Mouth Illness (HFMD) Vaccine By Investing.com
The primary section III medical trial of a multivalent HFMD vaccine on…
60 Levels Prescribed drugs Launches Scientific Trial of Babesiosis Drug By Investing.com
WASHINGTON - 60 Levels Prescribed drugs Inc. (NASDAQ: SXTP; SXTPW), an organization…
Scorpion Therapeutics Gives Scientific Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478 By Investing.com
“Entered into collaboration with Pfizer to judge the triple mixture of STX-478…
Investigational Epcoritamab (DuoBody ® CD3xCD20) Mixture Remedy Demonstrates Excessive Response Charges in Scientific Trial of Sufferers With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB):Outcomes present 96 p.c general response fee…
Investigational Epcoritamab (DuoBody ® CD3xCD20) Mixture Remedy Reveals Excessive Response Charges in Scientific Trial of Sufferers With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Knowledge offered on the 66th Annual Assembly and Exposition of the American…
Beam Therapeutics Announces New Data from the BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
All seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction >…
